**Background:** The ongoing COVID-19 pandemic caused by SARS-CoV-2 continues to pose a global public health crisis despite vaccine availability. The virus binds to host cellular angiotensin-converting enzyme-2 (ACE2) receptors and triggers a cytokine storm syndrome characterized by sustained elevation of proinflammatory cytokines including interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α). This leads to activation of macrophages, neutrophils, and T cells, followed by apoptosis of type 2 pneumocytes, resulting in acute respiratory distress syndrome, multiple organ failure, shock, and death. Hypoxemia and bilateral lung infiltration are features of severe COVID-19 pneumonia resulting from endothelial injury, cytokine storm, and immune overkill. The authors note a positive correlation between COVID-19 and vitamin D deficiency reported by many workers, and propose vitamin D as a potential therapeutic agent.
**Methods:** This is a correspondence article (letter to the editor) that reviews existing literature on the mechanisms of vitamin D in immune modulation and its potential relevance to COVID-19. The authors synthesize findings from prior studies on vitamin D receptor (VDR) signaling, cathelicidin expression, ACE2 receptor regulation, and cytokine modulation. They reference randomized trials and meta-analyses showing protective effects of vitamin D supplementation against SARS-CoV-2, though specific citations for these trials are limited in the text.
**Key Results:** The article describes multiple mechanisms by which vitamin D may exert protective effects against SARS-CoV-2: (1) Vitamin D binds to cytoplasmic VDRs, which dimerize with themselves or retinoid X receptors and translocate to the nucleus to bind VDR elements on DNA, regulating host genes such as β-defensin and cathelicidin. (2) Cathelicidins have antipathogenic activity against bacteria, viruses, and fungi, and exhibit antimicrobial activity by triggering inflammatory cascades and prompting chemotaxis of leukocytes. (3) Vitamin D boosts innate immunity by upregulating human cathelicidin LL-37 and defensins, and promotes continuing tight junctions, gap junctions, and adherens junctions. (4) Vitamin D clears pathogens from the respiratory tract by inducing multiple apoptotic and autophagic events in epithelial cells exposed to the virus. (5) Vitamin D regulates toll-like receptor expression and enhances nitric oxide release in macrophages and neutrophils. (6) Vitamin D plays a role in T-cell maturation and shifts Th17 cells toward regulatory T cells, leading to anti-inflammatory effects. (7) Vitamin D directly impedes the nuclear factor-κB pathway, leading to downregulation of proinflammatory cytokines such as IL-1, IL-6, IL-12, and TNF-α. (8) Downregulation of ACE2 receptors by vitamin D has been reported, and 1,25(OH)2D3 suppresses renin, ACE2+, and angiotensin II (Ang II) expression. Decreased Ang II and increased Ang (1–7) result in enhanced antioxidant properties, increased anti-inflammatory effects, increased antimicrobial peptides, reduced cytokine storm and apoptosis, and promoted Th2 phenotype polarization, decreasing viral uptake and disease severity.
**Clinical Implications:** The authors conclude that due to its all-round action from virus entry to disease progression until virus clearance, vitamin D may prove crucial in the management of severe COVID-19. They note that randomized trials and meta-analyses have shown protective effects of vitamin D supplementation against SARS-CoV-2, and owing to its antiviral and anti-inflammatory effects, it can be used in routine regimens for better disease management. The authors acknowledge that other mechanisms of the antiviral effect of vitamin D remain unexplored and call for further research, particularly for immune-compromised and high-risk individuals. The article does not provide specific dosage recommendations, effect sizes, or statistical data from clinical trials.